SCHEMBL27247482

SCHEMBL27247482

O=C(O)NCc1cc2cc(Cl)c([N+](=O)[O-])cc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
HTT P42858 2/20 0.48
MAPT P10636 4/20 0.39
EGLN1 Q9GZT9 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 2/20 0.39
CA12 O43570 2/20 0.38
CA9 Q16790 2/20 0.38
PKM P14618 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
HSP90AA1 P07900 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30946195 0.83 SMN1; SMN2 (0.46) SMN1; SMN2HTTMAPTNPC1RAB9A
SCHEMBL27246881 0.80 SMN1; SMN2 (0.46) SMN1; SMN2HTTMAPTNPC1RAB9A
SCHEMBL6160883 0.75 APEX1 (0.51) MAPTEGLN1ALDH1A1CA12CA9
SCHEMBL1726825 0.70 KDM1A (0.53) SMN1; SMN2HTTMAPTALDH1A1MAPK1
SCHEMBL27247586 0.69 RAB9A (0.46) SMN1; SMN2MAPTNPC1RAB9ACA12
SCHEMBL27385697 0.68 SMN1; SMN2 (0.46) SMN1; SMN2HTTMAPTNPC1RAB9A
SCHEMBL8108859 0.68 POLB (0.51) SMN1; SMN2MAPTNPC1ALDH1A1LMNA
SCHEMBL27247736 0.68 CA2 (0.43) SMN1; SMN2NPC1RAB9A
SCHEMBL27247899 0.68 RAB9A (0.45) SMN1; SMN2MAPTEGLN1NPC1RAB9A
SCHEMBL27382975 0.68 CACNA1G (0.48) SMN1; SMN2HTTMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 SMN1; SMN2 375/4885HTT 141/4885MAPT 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.